Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis

Interferon beta (IFNβ) is the most common immunomodulatory treatment for relapsing-remitting multiple sclerosis (RRMS). However, some patients fail to respond to treatment. In this study, we identified putative clinical response markers in the serum and plasma of people with multiple sclerosis (MS) treated with IFNβ. In a discovery-driven approach, we use 2D-difference gel electrophoresis (DIGE) to identify putative clinical response markers and apply power calculations to identify the sample size required to further validate those markers. In the process we have optimized a DIGE protocol for plasma to obtain cost effective and high resolution gels for effective spot comparison. APOA1, A2M, and FIBB were identified as putative clinical response markers. Power calculations showed that the current DIGE experiment requires a minimum of 10 samples from each group to be confident of 1.5 fold difference at the p<0.05 significance level. In a complementary targeted approach, Cytometric Beadarray (CBA) analysis showed no significant difference in the serum concentration of IL-6, IL-8, MIG, Eotaxin, IP-10, MCP-1, and MIP-1α, between clinical responders and non-responders, despite the association of these proteins with IFNβ treatment in MS.

[1]  H. Tumani,et al.  2D DIGE of the cerebrospinal fluid proteome in neurological diseases , 2010, Expert review of proteomics.

[2]  Yazhou Cui,et al.  Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis , 2009, Journal of cellular and molecular medicine.

[3]  A. Ludolph,et al.  CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis , 2009, Neuroscience Letters.

[4]  X. Montalban,et al.  Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. , 2009, Clinical immunology.

[5]  Zhaoyu Qin,et al.  Alteration of DBP Levels in CSF of Patients with MS by Proteomics Analysis , 2009, Cellular and Molecular Neurobiology.

[6]  R. Christopherson,et al.  Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions. , 2007, Biochimica et biophysica acta.

[7]  G. Horgan,et al.  Sample size and replication in 2D gel electrophoresis studies. , 2007, Journal of proteome research.

[8]  A. Minagar,et al.  Proteomic Analysis of Human Cerebral Endothelial Cells Activated by Multiple Sclerosis Serum and IFNβ-1b , 2007, Journal of Molecular Neuroscience.

[9]  A. Minagar,et al.  Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b. , 2007, Journal of molecular neuroscience : MN.

[10]  S. Sakoda,et al.  Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection. , 2006, Cytokine.

[11]  R. Bergamaschi,et al.  Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis , 2006, Journal of the Neurological Sciences.

[12]  Justin C McArthur,et al.  Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis , 2006, Annals of neurology.

[13]  C. Boz,et al.  Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing–remitting multiple sclerosis treated with interferon beta , 2006, Clinical Neurology and Neurosurgery.

[14]  R. Ransohoff,et al.  The expression and function of chemokines involved in CNS inflammation. , 2006, Trends in pharmacological sciences.

[15]  J. Granger,et al.  Albumin depletion of human plasma also removes low abundance proteins including the cytokines , 2005, Proteomics.

[16]  Kathryn S Lilley,et al.  Impact of replicate types on proteomic expression analysis. , 2005, Journal of proteome research.

[17]  Edmond J. Breen,et al.  New urinary EPO drug testing method using two-dimensional gel electrophoresis. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[18]  H. Hartung,et al.  Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference , 2005, European journal of neurology.

[19]  M. Wilkins,et al.  Optimal replication and the importance of experimental design for gel-based quantitative proteomics. , 2005, Journal of proteome research.

[20]  C. Pozzilli,et al.  Interferon beta-1b in secondary progressive MS , 2004, Neurology.

[21]  P. Sørensen,et al.  Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis. , 2004, Biochimica et biophysica acta.

[22]  M. Buttmann,et al.  Interferon-β induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis , 2004, Journal of Neuroimmunology.

[23]  S. Groshen,et al.  Increased CXCL8 (IL-8) expression in Multiple Sclerosis , 2004, Journal of Neuroimmunology.

[24]  A. Lutterotti,et al.  Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity , 2004, Multiple sclerosis.

[25]  M. Pender,et al.  Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. , 2004, Current drug targets. Inflammation and allergy.

[26]  Jean-Paul Noben,et al.  Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients , 2004, Proteomics.

[27]  S. Hunsucker,et al.  Proteomic analysis of multiple sclerosis cerebrospinal fluid , 2004, Multiple sclerosis.

[28]  M. Buttmann,et al.  Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. , 2004, Journal of neuroimmunology.

[29]  J. Losy,et al.  Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis. , 2004, Folia neuropathologica.

[30]  P. Sørensen,et al.  Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.

[31]  Josemir W Sander,et al.  Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management , 2003, Acta neurologica Scandinavica. Supplementum.

[32]  K. Nicolay,et al.  Interferon-Beta Prevents Cytokine-Induced Neutrophil Infiltration and Attenuates Blood–Brain Barrier Disruption , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  S. Vukusic,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[34]  P. Sundström,et al.  Native and transformed α2‐macroglobulin in plasma from patients with multiple sclerosis , 2003, Acta neurologica Scandinavica.

[35]  J. Lünemann,et al.  TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis , 2003, The Lancet.

[36]  Stephen O. David,et al.  A novel experimental design for comparative two‐dimensional gel analysis: Two‐dimensional difference gel electrophoresis incorporating a pooled internal standard , 2003, Proteomics.

[37]  P. Rieckmann,et al.  Early intervention in multiple sclerosis : better outcomes for patients and society? , 2003, Drugs.

[38]  D. Jeffery.  Early intervention with immunomodulatory agents in the treatment of multiple sclerosis , 2002, Journal of the Neurological Sciences.

[39]  H. Weiner,et al.  Interferon-β treatment alters peripheral blood monocytes chemokine production in MS patients , 2002, Journal of Neuroimmunology.

[40]  D. Gambi,et al.  Interferon β-1b modulates MCP-1 expression and production in relapsing–remitting multiple sclerosis , 2002, Journal of Neuroimmunology.

[41]  D. Gambi,et al.  Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. , 2002, Journal of neuroimmunology.

[42]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[43]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[44]  F. Jungo,et al.  IFN-β INHIBITS THE ABILITY OF T LYMPHOCYTES TO INDUCE TNF-α AND IL-1β PRODUCTION IN MONOCYTES UPON DIRECT CELL–CELL CONTACT , 2001 .

[45]  P. Righetti,et al.  Protein alkylation in the presence/absence of thiourea in proteome analysis: A matrix assisted laser desorption/ionization‐time of flight‐mass spectrometry investigation , 2001, Electrophoresis.

[46]  N. Hyka,et al.  Articles on similar topics can be found in the following Blood collections , 2013 .

[47]  P. Calabresi,et al.  T lymphocytes conditioned with Interferon β induce membrane and soluble VCAM on human brain endothelial cells , 2001, Journal of Neuroimmunology.

[48]  B. Bergamasco,et al.  Interferon-β dose and efficacy: the OPTIMS study , 2001, Neurological Sciences.

[49]  T. Williams,et al.  Eotaxin and the attraction of eosinophils to the asthmatic lung , 2001, Respiratory research.

[50]  V. Rivera,et al.  Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1α by interferon-β , 2001, Journal of Neuroimmunology.

[51]  V. Rivera,et al.  Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. , 2001, Journal of neuroimmunology.

[52]  F. Jungo,et al.  IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. , 2001, Cytokine.

[53]  B. Bergamasco,et al.  Interferon-beta dose and efficacy: the OPTIMS study. , 2001, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[54]  A. Roessner,et al.  Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and α2-macroglobulin in cases of generalized AA- and AL amyloidosis , 2000, Virchows Archiv.

[55]  F. Nicoletti,et al.  SHORT-TERM TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS WITH INTERFERON (IFN)-β1B TRANSIENTLY INCREASES THE BLOOD LEVELS OF INTERLEUKIN (IL)-6, IL-10 AND IFN-γ WITHOUT SIGNIFICANTLY MODIFYING THOSE OF IL-1β, IL-2, IL-4 AND TUMOUR NECROSIS FACTOR-α , 2000 .

[56]  R. Pedrosa,et al.  Interferon β1a Therapy Changes Lipoprotein Metabolism in Patients with Multiple Sclerosis , 2000 .

[57]  R. Pedrosa,et al.  Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis. , 2000, Clinical chemistry and laboratory medicine.

[58]  J. Gutiérrez-Ramos,et al.  Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. , 1999, Immunology today.

[59]  V. Rivera,et al.  Interferon beta induces T-helper 2 immune deviation in MS , 1999, Neurology.

[60]  J. Gamble,et al.  Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. , 1999, Journal of lipid research.

[61]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.